BMJ

Evaluation of the efficacy and safety of etoricoxib compared with naproxen in two, 138-week randomised studies of patients with osteoarthritis

2 Clinical Immunology and Analgesia, Merck Research Laboratories, Rahway, USA Correspondence to: Dr S P Curtis Merck Research Laboratories, PO Box 2000, Rahway, New Jersey, USA; ...
BMJ

A nationwide non-medical switch from originator infliximab to biosimilar CT-P13 in 802 patients with inflammatory arthritis: 1-year clinical outcomes from the DANBIO registry

1 The DANBIO registry and Copenhagen Center for Arthritis Research (COPECARE), Center for Rheumatology and Spine Diseases, Centre of Head and Orthopaedics, Rigshospitalet, Glostrup, Denmark Objectives ...
BMJ

QUEST-RA: quantitative clinical assessment of patients with rheumatoid arthritis seen in standard rheumatology care in 15 countries

Objective: To conduct a cross-sectional review of non-selected consecutive outpatients with rheumatoid arthritis (RA) as part of standard clinical care in 15 countries for an overview of the ...
BMJ

Paracetamol and cyclooxygenase inhibition: is there a cause for concern?

1 Institute of Toxicology and Pharmacology, University of Rostock, Rostock, Germany 2 Department of Experimental and Clinical Pharmacology and Toxicology, Friedrich Alexander University ...
BMJ

AB0021 REAL LIFE DATA ON TAPERING AND DISCONTINUATION OF ANAKINRA TREATMENT IN RECURRENT PERICARDITIS: AN INTERNATIONAL REGISTRY

2 University of Torino, Department of Medical Sciences, Città Della Salute E Della Scienza Di Torino Hospital, Torino, Italy 3 Department of Medical Sciences, Surgery and Neurosciences, Research ...
BMJ

Primary Sjögren's syndrome and malignancy risk: a systematic review and meta-analysis

Department of Laboratory Diagnostics, Changzheng Hospital, Second Military Medical University, Shanghai, China Correspondence to Dr Yang Zaixing and Professor Renqian Zhong, Department of Laboratory ...
BMJ

Table of contents

SpA: Innovative techniques in spondyloarthritis research – Is there light at the end of the tunnel for our patients?
BMJ

EULAR recommendations for the treatment of systemic sclerosis: 2023 update

Objectives To update the 2017 European Alliance of Associations for Rheumatology (EULAR) recommendations for treatment of systemic sclerosis (SSc), incorporating new evidence and therapies. Methods An ...
BMJ

Real-life use of the PEXIVAS reduced-dose glucocorticoid regimen in granulomatosis with polyangiitis and microscopic polyangiitis

3 Centre de Recherche en Epidémiologie et Statistiques (CRESS), Unité Inserm 1153, Université Paris Cité, Paris, France ...
BMJ

The squeeze test of MCP joints: a scarcity of scientific data, especially from primary care

1 Department of Rheumatology, Leiden University Medical Center, Leiden, The Netherlands 2 Department of Rheumatology, Erasmus Medical Center, Rotterdam, The Netherlands Correspondence to A H M van der ...
BMJ

CD-19 CAR-T cells for polyrefractory rheumatoid arthritis

‘Poly-refractory’ disease affects 2.7% of patients with rheumatoid arthritis (RA) who have failed different groups of biologic disease-modifying antirheumatic drugs (b-DMARDS) and targeted synthetic ...
BMJ

Relationship between serum urate and changes in dual-energy CT monosodium urate crystal volume over 1 year in people with gout: an individual participant data analysis

Objectives The dynamics of monosodium urate (MSU) crystal changes across a range of serum urate concentrations in people with gout are unknown. This study aimed to systematically examine the ...